Selma Audi1, Daniel R Burrage1,2, Dagan O Lonsdale1,2, Sarah Pontefract3,4, Jamie J Coleman3,4, Andrew W Hitchings5,2, Emma H Baker1,2. 1. Clinical Pharmacology, Institute of Infection and Immunity, St George's, University of London. 2. St George's University Hospitals NHS Foundation Trust. 3. Institute of Clinical Sciences, University of Birmingham. 4. University Hospital Birmingham NHS Foundation Trust. 5. Clinical Pharmacology, Institute of Medical and Biomedical Education, St George's, University of London.
Abstract
AIMS: Prescribing is a complex skill required of doctors and, increasingly, other healthcare professionals. Use of a personal formulary can help to develop this skill. In 2006-9, we developed a core list of the 100 most commonly prescribed drugs. Our aim in the present study was to update this 'starter formulary' to ensure its continued relevance for prescriber training. METHODS: We analysed large contemporary primary and secondary care datasets to identify the most frequently prescribed medicinal products. Items were classified into natural groups, broadly following their British National Formulary classification. The resulting drug groups were included in the core list if they comprised ≥0.1% prescriptions in both settings or ≥0.2-0.3% prescriptions in one setting. Drugs from emergency guidelines that did not qualify by prescribing frequency completed the list. RESULTS: Over 1 billion primary care items and approximately 1.8 million secondary care prescriptions were analysed. The updated list comprises 81 drug groups commonly prescribed in both settings; six from primary care; seven from secondary care; and six from emergency guidelines. Eighty-eight per cent of the formulary was unchanged. Notable changes include entry of newer anti-epileptics and dipeptidyl peptidase-4 inhibitors and exit of phenytoin and thiazolidinediones. CONCLUSIONS: The relative stability of the core drug list over 9 years and the current update ensure that learning based on this list remains relevant to practice. Trainee prescribers may be encouraged to use this 'starter formulary' to develop a sound basis of prescribing knowledge and skills that they can subsequently apply more widely.
AIMS: Prescribing is a complex skill required of doctors and, increasingly, other healthcare professionals. Use of a personal formulary can help to develop this skill. In 2006-9, we developed a core list of the 100 most commonly prescribed drugs. Our aim in the present study was to update this 'starter formulary' to ensure its continued relevance for prescriber training. METHODS: We analysed large contemporary primary and secondary care datasets to identify the most frequently prescribed medicinal products. Items were classified into natural groups, broadly following their British National Formulary classification. The resulting drug groups were included in the core list if they comprised ≥0.1% prescriptions in both settings or ≥0.2-0.3% prescriptions in one setting. Drugs from emergency guidelines that did not qualify by prescribing frequency completed the list. RESULTS: Over 1 billion primary care items and approximately 1.8 million secondary care prescriptions were analysed. The updated list comprises 81 drug groups commonly prescribed in both settings; six from primary care; seven from secondary care; and six from emergency guidelines. Eighty-eight per cent of the formulary was unchanged. Notable changes include entry of newer anti-epileptics and dipeptidyl peptidase-4 inhibitors and exit of phenytoin and thiazolidinediones. CONCLUSIONS: The relative stability of the core drug list over 9 years and the current update ensure that learning based on this list remains relevant to practice. Trainee prescribers may be encouraged to use this 'starter formulary' to develop a sound basis of prescribing knowledge and skills that they can subsequently apply more widely.
Authors: Selma Audi; Daniel R Burrage; Dagan O Lonsdale; Sarah Pontefract; Jamie J Coleman; Andrew W Hitchings; Emma H Baker Journal: Br J Clin Pharmacol Date: 2018-08-10 Impact factor: 4.335
Authors: Thomas Bleck; Hannah Cock; James Chamberlain; James Cloyd; Jason Connor; Jordan Elm; Nathan Fountain; Elizabeth Jones; Daniel Lowenstein; Shlomo Shinnar; Robert Silbergleit; David Treiman; Eugen Trinka; Jaideep Kapur Journal: Epilepsia Date: 2013-09 Impact factor: 5.864
Authors: T P G M De Vries; J M A Daniels; C W Mulder; O A Groot; L Wewerinke; K I Barnes; H A Bakathir; N A G M Hassan; L Van Bortel; M Kriska; B Santoso; E J Sanz; M Thomas; L E Ziganshina; P D Bezemer; C Van Kan; M C Richir; H V Hogerzeil Journal: Eur J Clin Pharmacol Date: 2008-06 Impact factor: 2.953
Authors: James E Kimpton; Iain M Carey; Christopher J D Threapleton; Alexandra Robinson; Tess Harris; Derek G Cook; Stephen DeWilde; Emma H Baker Journal: Br J Clin Pharmacol Date: 2019-12-13 Impact factor: 4.335
Authors: Selma Audi; Daniel R Burrage; Dagan O Lonsdale; Sarah Pontefract; Jamie J Coleman; Andrew W Hitchings; Emma H Baker Journal: Br J Clin Pharmacol Date: 2018-08-10 Impact factor: 4.335
Authors: Christopher J D Threapleton; James E Kimpton; Iain M Carey; Stephen DeWilde; Derek G Cook; Tess Harris; Emma H Baker Journal: Br J Clin Pharmacol Date: 2020-03-16 Impact factor: 4.335
Authors: Mark Gormley; James Yarmolinsky; Tom Dudding; Kimberley Burrows; Richard M Martin; Steven Thomas; Jessica Tyrrell; Paul Brennan; Miranda Pring; Stefania Boccia; Andrew F Olshan; Brenda Diergaarde; Rayjean J Hung; Geoffrey Liu; Danny Legge; Eloiza H Tajara; Patricia Severino; Martin Lacko; Andrew R Ness; George Davey Smith; Emma E Vincent; Rebecca C Richmond Journal: PLoS Genet Date: 2021-04-22 Impact factor: 5.917
Authors: Erik Donker; David Brinkman; Milan Richir; Paraskevi Papaioannidou; Robert Likic; Emilio J Sanz; Thierry Christiaens; João Costa; Fabrizio De Ponti; Milo Gatti; Ylva Böttiger; Cornelis Kramers; Sarah Garner; Rahul Pandit; Michiel van Agtmael; Jelle Tichelaar Journal: BMJ Open Date: 2021-05-04 Impact factor: 2.692